Chongqing Zhifei Biological Products Co., Ltd. (SHE:300122)

China flag China · Delayed Price · Currency is CNY
23.82
-0.27 (-1.12%)
Aug 1, 2025, 2:45 PM CST
-1.12%
Market Cap57.09B
Revenue (ttm)17.05B
Net Income (ttm)255.59M
Shares Out2.39B
EPS (ttm)0.11
PE Ratio223.50
Forward PE39.44
Dividend0.20 (0.83%)
Ex-Dividend DateDec 25, 2024
Volume48,781,530
Average Volume55,240,288
Open25.16
Previous Close24.09
Day's Range23.79 - 25.16
52-Week Range18.70 - 40.43
Beta1.20
RSI65.00
Earnings DateAug 19, 2025

About HashiCorp

Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal Polysaccharide Vaccine under the Menwayc brand; Mycobacterium Vaccae for Injection under the Vaccae brand; Meningococcal Group A and Group C Polysacchar... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 7,220
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300122
Full Company Profile

Financial Performance

In 2024, SHE:300122's revenue was 26.07 billion, a decrease of -50.74% compared to the previous year's 52.92 billion. Earnings were 2.02 billion, a decrease of -74.99%.

Financial Statements

News

There is no news available yet.